Tomasz Kostrzewa1, Joanna Styszko1, Magdalena Gorska-Ponikowska1, Tomasz Sledzinski2, Alicja Kuban-Jankowska3. 1. Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland. 2. Department of Pharmaceutical Biochemistry, Medical University of Gdansk, Gdansk, Poland. 3. Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland alicja.kuban-jankowska@gumed.edu.pl.
Abstract
BACKGROUND/AIM: PTP1B tyrosine phosphatase is involved in the development of many types of cancers, such as breast cancer or lung cancer. Therefore, PTP1B is a promising target for anticancer therapy. The purpose of this review was to present the studies on selected PTP1B inhibitors as a possible treatment and describe the latest trends of current research in this field. MATERIALS AND METHODS: This literature review was performed using the PubMed database and the analysis of previous research studies of our Department. RESULTS: Recent studies have shown that PTP1B, due to its implication in oncogenic transformation, represents a promising drug target. CONCLUSION: The selected compounds that are effective PTP1B inhibitors can be considered a promising anticancer treatment, both as monotherapy and in combination with other anticancer drugs. Copyright
BACKGROUND/AIM: PTP1B tyrosine phosphatase is involved in the development of many types of cancers, such as breast cancer or lung cancer. Therefore, PTP1B is a promising target for anticancer therapy. The purpose of this review was to present the studies on selected PTP1B inhibitors as a possible treatment and describe the latest trends of current research in this field. MATERIALS AND METHODS: This literature review was performed using the PubMed database and the analysis of previous research studies of our Department. RESULTS: Recent studies have shown that PTP1B, due to its implication in oncogenic transformation, represents a promising drug target. CONCLUSION: The selected compounds that are effective PTP1B inhibitors can be considered a promising anticancer treatment, both as monotherapy and in combination with other anticancer drugs. Copyright
Authors: Matteo Accorsi; Markus Tiemann; Leon Wehrhan; Lauren M Finn; Ruben Cruz; Max Rautenberg; Franziska Emmerling; Joachim Heberle; Bettina G Keller; Jörg Rademann Journal: Angew Chem Int Ed Engl Date: 2022-04-25 Impact factor: 16.823
Authors: Jing Xie; Ying-Yan Qian; Yang Yang; Lin-Jie Peng; Jia-Ying Mao; Ming-Rong Yang; Yang Tian; Jun Sheng Journal: Front Cell Dev Biol Date: 2022-01-04
Authors: Caroline E Nunes-Xavier; Laura Zaldumbide; Lorena Mosteiro; Ricardo López-Almaraz; Nagore García de Andoin; Pablo Aguirre; Maite Emaldi; Leire Torices; José I López; Rafael Pulido Journal: Front Cell Dev Biol Date: 2021-12-08